Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management

Advisory committee members are generally comfortable with use of the GLP-1 receptor agonist in the first-line setting, suggesting that a second-line treatment restriction in diabetes could be lifted.

More from United States

More from North America